Global Digital Therapeutics Market valued at $2.2bn, poised to transform the Digital Health Segment
The global digital therapeutics market pegged at $2.2 billion (2020) is set to gain momentum. The next phase of growth likely to be driven by growing pharma-digital therapeutic alliances, growing focus on mental health and psychiatric conditions.
Digital therapeutics is poised to revolutionize the healthcare industry. It finds usage across a range applications such as Diabetes, Chronic Respiratory Disorders, Musculoskeletal Disorders, Smoking Cessation, Cardiovascular Diseases, CNS Disorders, Obesity and Others. It offers immense value for multiple stakeholders. Key stakeholders such as FDA, HCPs, Payers, and Patients are now increasing embracing digital therapeutics as a form of therapy.
Geographic Snapshot: Digital Therapeutics Market
Comprehensive regional assessment of the global digital therapeutics market covering U.S., Europe (Germany, Italy, France, Spain, UK, and Rest of Europe), Asia-Pacific (India, China, Japan, Australia, New Zealand, Singapore and Rest of Asia-Pacific)
Psychiatry Remains #1 Application in Clinical Trials of Digital Therapeutics
A review of trends of digital therapeutics clinical trials over the past ten years suggests that with respect to therapeutic areas (TA) under investigation, the highest percentage of trials were conducted for psychiatry indication followed by cardiovascular, addiction, endocrinology, neurology, and respiratory indications. Strong pipeline of digital therapeutics products across diverse application areas – neuroscience indications, cardiovascular diseases, gastrointestinal diseases, chronic kidney disease (CKD), among others is likely to provide impetus to the global digital therapeutics market.
For Detailed Insights, Reach out to us @ https://meditechinsights.com/
+ 32 498868079